Hubei Hendi Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the board guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.
I. Review Procedure
The Company held the 18th meeting of the second board of directors on March 30, 2026, to review and approve the "2025 Profit Distribution Plan," which will be submitted to the 2025 annual shareholders' meeting for consideration.
II. Basic Situation of the Profit Distribution Plan
According to the audit by Da Xin Accounting Firm (Special General Partnership), the Company achieved a net profit attributable to shareholders of the listed company of RMB 34,910,598.79 for the 2025 consolidated financial statements, and the parent company achieved a net profit of RMB 30,953,498.69. The statutory surplus reserve fund of RMB 3,095,349.87 was allocated based on 10% of the parent company's net profit for the year. As of December 31, 2025, the distributable profits of the parent company amounted to RMB 178,412,837.59, while the cumulative distributable profits of the consolidated financial statements were RMB 167,369,975.84.